Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Virios Therapeutics, Inc. VIRI

Set alert

Price alert · VIRI

All alert types
0.16 +0.16 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
206.50K
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-0.97
Beta
1.58
Short ratio
0.64
Inst. own
0.00%
Dividend
0.00
Ex-div date
Earnings
Nov 11, 2024
50-d avg
4.51
200-d avg
7.69
1y target
3.00

2Y chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 10, 2023Earnings: —; estimate -0.07; surprise —%
  • Nov 13, 2023Earnings: —; estimate -0.1; surprise —%
  • Feb 29, 2024Earnings: —; estimate -0.09; surprise —%
  • May 9, 2024Earnings: —; estimate -0.08; surprise —%
  • Aug 8, 2024Earnings: —; estimate -0.07; surprise —%
  • Oct 9, 2024Split: 1 for 25
Signals (70)
NameDateAgo
SMA: BullishNov 4, 20241 year ago
SMA: BearishOct 29, 20242 years ago
SMA: BullishOct 24, 20242 years ago
MACD: Buy SignalOct 14, 20242 years ago
MACD: Sell SignalSep 26, 20242 years ago
MACD: Buy SignalSep 11, 20242 years ago
MACD: Sell SignalSep 4, 20242 years ago
SMA: BearishAug 22, 20242 years ago
SMA: BullishAug 21, 20242 years ago
MACD: Buy SignalAug 16, 20242 years ago
MACD: Sell SignalJul 24, 20242 years ago
SMA: BearishJul 19, 20242 years ago
SMA: BullishJul 17, 20242 years ago
MACD: Buy SignalJun 5, 20242 years ago
RSI: OversoldMay 20, 20242 years ago
SMA: BearishMay 9, 20242 years ago
SMA: BullishMay 8, 20242 years ago
SMA: BearishMay 3, 20242 years ago
MACD: Sell SignalApr 16, 20242 years ago
SMA: BullishMar 22, 20242 years ago

Newest 20 of 70.

Key statistics

Financials
Market cap
206.50K
Enterprise value
122.01K
Trailing P/E
0.00
Forward P/E
-0.97
PEG ratio
0.00
Price / sales
0.00
Price / book
0.05
EPS (TTM)
-5.75
Beta
1.58
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-2.43M
Total cash
3.02M
Total debt
0
Return on equity
-119.56%
Shares outstanding
1.33M
Short % of float
1.76%
50-day average
4.51
200-day average
7.69

Analyst view

Consensus: buy

Buy
Price target (mean) 3.00 +1835.5% upside
Target (low)
1.00
Target (mean)
3.00
Target (high)
5.00

Next earnings

Nov 11, 2024

Expected Nov 11, 2024. Consensus EPS estimate -0.05.

Earnings history

Financials — quick view

All financials
VIRI Revenue — quarterly 0
2020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-30
VIRI Net income — quarterly -1.05M
2020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-30
VIRI EPS — quarterly -0.05
2020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-30

Earnings

VIRI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 11, 2024Sep 1, 2024-0.06———
Aug 8, 2024Jun 1, 2024-0.07———
May 9, 2024Mar 1, 2024-0.08———
Feb 29, 2024Dec 1, 2023-0.09———
Nov 13, 2023Sep 1, 2023-0.10———
Aug 10, 2023Jun 1, 2023-0.07———

Upgrades / downgrades

VIRI analyst upgrades and downgrades
DateFirmActionFromTo
Sep 19, 2022HC Wainwright & Co.downBuyNeutral
Dec 14, 2021HC Wainwright & Co.init—Buy

About Virios Therapeutics, Inc.

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
virios.com

News

All news

Your note

Sign in to keep a note on VIRI — it syncs with the Stock Master app.

Insider holders

VIRI insider holders
InsiderRelationLatest transactionDateShares held
DUNCAN GREGORY SCOTTChief Executive OfficerPurchaseAug 16, 202357,461
PRIDGEN WILLIAM LDirectorPurchaseAug 20, 20230
WHITLEY RICHARD JAMESDirectorSaleDec 7, 2022700

Institution ownership

VIRI institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc1.10%210,996291.17KJun 29, 2023
Geode Capital Management, LLC0.77%147,269203.23KJun 29, 2023
State Street Corporation0.27%52,82872.90KJun 29, 2023
Susquehanna International Group, LLP0.27%52,63972.64KJun 29, 2023
Renaissance Technologies, LLC0.24%46,40064.03KJun 29, 2023
Citadel Advisors Llc0.17%33,29845.95KJun 29, 2023

Fund ownership

VIRI fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund1.09%208,883288.26KJun 29, 2023
Fidelity Extended Market Index Fund0.70%134,121230.69KMay 30, 2023
Fidelity Series Total Market Index Fund0.17%33,48557.59KMay 30, 2023
Fidelity Total Market Index Fund0.08%14,70725.30KMay 30, 2023
Fidelity NASDAQ Composite Index Fund0.02%3,0385.22KMay 30, 2023

Splits

VIRI stock splits
DateRatio
Oct 9, 20241:25